NxStage Medical Surges Nearly 8% After Beating Wall Street
NxStage Medical tops Wall Street's forecasts for both sales and losses, sending share prices up nearly 8% today.
The Lawrence, Mass.-based medical device company said it pared its 4th-quarter losses by nearly 50%, to $2.4 million or 4¢ per share, on sales of $65.0 million for the 3 months ended Dec. 31, 2012. That amounts to top-line growth of 14.0% compared with Q4 2011.
For the full year, NxStage said losses were $14.6 million or 26¢ per share, down 32.2% compared with 2011.